Oslo Norway, November 18, 2022. The LINK Medical Board is pleased to announce the appointment of Sissel Lønning Andresen as the new CEO of LINK Medical. Sissel will assume the position as the CEO of the company as of January 1st, 2023.
Sissel has a Master of Science in pharmacy and brings nearly 25 years of experience from the pharmaceutical industry, holding several positions within regulatory, sales, marketing, market access, and public affairs. For the last nine years, she has been the CEO of Pfizer Norway and has created strong business results during her tenure at the company. Prior to this, she held several different roles at Pfizer and has also worked at Pharmacia and GE Healthcare.
Ola Gudmundsen will remain in the company in a strategic role where he will work closely with Sissel and support the Business Development and Commercial Operations team. He will remain an important owner of the company and continue to serve on the board of LINK Medical.
Chairman Michael Bodd states: “I’m delighted to welcome Sissel as the new CEO of LINK Medical. We look forward to the next phase of LINK’s development under Sissel’s leadership. She has an impressive track record and will contribute with comprehensive industry knowledge and build on our existing strengths, to accelerate growth and profitability in our key business areas”.
Ola Gudmundsen said: “I’m confident that Sissel will lead LINK Medical forward into the next phase of development. Sissel will further strengthen LINK Medical’s position as the leading North European CRO and capture the many exciting opportunities that lay ahead of us.”
Sissel Lønning Andresen states: “I’m thrilled and humbled to start the role as new CEO of LINK Medical at such a pivotal time and look forward to meeting my new colleagues across all departments. LINK has a great reputation of delivering high-quality services to the life science industry, and together with the highly skilled staff we will build and develop the company into its next chapter of growth”.